Govantes M A Gentil, Esteve A Franco, Ramos M Toro, Gracia De Guindo M C, Sánchez L Fuentes, Blanca M A Mazuecos, Rodríguez-Benot A, Blandino M Vidal, De la Nuez P Castro, Rodríguez D Burgos
Service of Nephrology, Virgen del Rocio University Hospital, Seville, Spain.
Transplant Proc. 2013;45(10):3592-4. doi: 10.1016/j.transproceed.2013.10.030.
Post-transplantation lymphoproliferative disease (PTLD) is a severe complication of renal transplantation (RT) but information about its incidence and predisposing factors is diverse, varying according to geographic area and study period.
We analyzed the incidence of PTLD after all RT performed at adult transplantation centers in Andalusia from January 1, 1990 to December 31, 2009, recorded in the Andalusian Transplant Co-ordination Information System (SICATA) regional computerized database (n = 5577). We calculated the risk of PTLD using the Kaplan-Meier curve, censoring for organ failure and incidence rate per patient-year of exposure. Log-rank comparisons were made by center (n = 5), decade (1990-1999 vs 2000-2009), age group, recipient gender, hepatitis C virus (HCV) serology, transplantation number, and duration of pre-RT replacement therapy (per quartiles).
We identified 60 cases of PTLD. The pre-RT treatment time was 48.2 ± 60 months; 11.7% were retransplantations, and 10.4% had a positive HCV serology. The median post-RT time before diagnosis of PTLD was 5.98 years. At the time of the database analysis, only 11 patients (18%) were alive with a functioning transplant; 10% had returned to dialysis and 72% had died. The actuarial incidence of PTLD at 1, 5, 10, and 20 years post-RT was 0.2%, 0.5%, 1.6%, and 2.9%, respectively; the exposure rate was 14.71 PTLD/10,000 patient-years (95% confidence interval [CI], 12.3-17.1). Although the incidence tended to be higher in 1990-1999 than 2000-2009 (16.8 vs 12.1 cases/10,000 patient-years), in the actuarial study the difference was far from significant (at 7.5 years, 1.2 vs 0.8%; P = .4). Nor were there significant differences in the curves of incidence per RT center (1%-1.2% of patients) or recipient characteristics.
The cumulative incidence of PTLD in Andalusia in patients with a functioning kidney transplant during 1990-2009 was 2.9% at 20 years. There was no significant variation between the RT centers or over time. No associated factors were identified among the basic recipient variables studied.
移植后淋巴细胞增生性疾病(PTLD)是肾移植(RT)的一种严重并发症,但关于其发病率和易感因素的信息各不相同,因地理区域和研究时期而异。
我们分析了1990年1月1日至2009年12月31日在安达卢西亚成人移植中心进行的所有肾移植术后PTLD的发病率,这些数据记录在安达卢西亚移植协调信息系统(SICATA)的区域计算机数据库中(n = 5577)。我们使用Kaplan-Meier曲线计算PTLD的风险,以器官衰竭为删失指标,并计算每位患者每年的暴露发病率。通过中心(n = 5)、十年(1990 - 1999年与2000 - 2009年)、年龄组、受者性别、丙型肝炎病毒(HCV)血清学、移植次数以及肾移植前替代治疗持续时间(按四分位数)进行对数秩比较。
我们确定了60例PTLD病例。肾移植前治疗时间为48.2 ± 60个月;11.7%为再次移植,10.4%的HCV血清学检测呈阳性。诊断PTLD前的肾移植后中位时间为5.98年。在数据库分析时,只有11例患者(18%)移植肾功能良好存活;10%已恢复透析,72%已死亡。肾移植后1年、5年、10年和20年PTLD的精算发病率分别为0.2%、0.5%、1.6%和2.9%;暴露率为14.71例PTLD/10000患者年(95%置信区间[CI],12.3 - 17.1)。尽管1990 - 1999年的发病率往往高于2000 - 2009年(16.8对12.1例/10000患者年),但在精算研究中差异远不显著(7.5年时,1.2%对0.8%;P = 0.4)。各肾移植中心的发病率曲线(患者的1% - 1.2%)或受者特征也无显著差异。
1990 - 2009年安达卢西亚肾移植功能良好患者中PTLD的累积发病率在20年时为2.9%。肾移植中心之间或随时间没有显著差异。在所研究的基本受者变量中未发现相关因素。